MDGL Stock — Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. (MDGL)

Updated October 16, 2026.

MDGL is a Stock. Total return is 41.4% over the past 19.7 years, 613.7 points behind SPY at 655.1%.

Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease. The company's lead product is Rezdiffra, a liver-directed thyroid hormone receptor beta agonist approved for treating MASH in the United States. Madrigal does not currently distribute dividends and is oriented toward investors seeking capital appreciation rather than income.

MDGL performance versus SPY

Price and return data through 2026-10-16.

Total return is 41.4% over the past 19.7 years, 613.7 points behind SPY at 655.1%. Over the past year its total return — price change plus distributions reinvested — is 1.7%. Its deepest 1-year drawdown was 29.4%.

MDGL key facts

Asset type

Stock

Asset class

Equity

Inception date

02/06/2007

Distribution frequency

None

Last close

$449.74 (as of 2026-10-16)

Market cap

$10,390,849,627

Average volume

364530.0

Payment date

07/25/2016

Beta

-1.052

Payout ratio

0.0%

Forward P/E

78.125

EPS

$-13.07

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MDGL risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 29.4%.

Who may consider MDGL — and who may not

It is a weaker fit for investors who need monthly cash flow (MDGL does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on MDGL

• All tickers starting with M

Tagged: Healthcare.

Frequently asked questions